4.7 Review

Hypoxia signaling in human diseases and therapeutic targets

Journal

EXPERIMENTAL AND MOLECULAR MEDICINE
Volume 51, Issue -, Pages -

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/s12276-019-0235-1

Keywords

-

Funding

  1. AHA Predoctoral Fellowship Grant [18PRE33960076]
  2. National Institute of Health [R01-DK109574, U01-AA021723, R21-AA024636]
  3. [R01-DK097075]
  4. [POI-HL114457]
  5. [R01-HL109233]
  6. [R01-HL119837]
  7. [R01-HL133900]

Ask authors/readers for more resources

Since the discovery of hypoxia-inducible factor (HIF), numerous studies on the hypoxia signaling pathway have been performed. The role of HIF stabilization during hypoxia has been extended from the induction of a single gene erythropoietin to the upregulation of a couple of hundred downstream targets, which demonstrates the complexity and importance of the HIF signaling pathway. Accordingly, HIF and its downstream targets are emerging as novel therapeutic options to treat various organ injuries. In this review, we discuss the current understanding of HIF signaling in four different organ systems, including the heart, lung, liver, and kidney. We also discuss the divergent roles of HIF in acute and chronic disease conditions and their revealed functions. Finally, we introduce some of the efforts that are being performed to translate our current knowledge in hypoxia signaling to clinical medicine.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available